Class / Patent application number | Description | Number of patent applications / Date published |
514500800 | Leptin or derivative affecting or utilizing | 24 |
20110003738 | AZINONE-SUBSTITUTED AZAPOLYCYCLE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF - Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are also described in the present invention. | 01-06-2011 |
20110003739 | AZINONE-SUBSTITUTED AZABICYCLOALKANE-INDOLE AND AZABICYCLOALKANE-PYRROLO-PYRIDINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF - Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are also described in the present invention. | 01-06-2011 |
20110034377 | Exendin and Exendin Agonists for Eating Disorders - Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed. | 02-10-2011 |
20110098219 | System for Curing Hepatic Cancer with Leptin - The present invention cures hepatic cancer by MPA with the help of leptin. A therapeutic drug of MPA combined with leptin is applied to a liver cancer patient. Or, MPA can be directly applied to a patient having a high leptin expression. Or, if a patient has a low leptin expression, MPA is applied to the patient after leptin expression is increased. Hence, expression of leptin can be taken as a predictive factor and a prognostic factor of treatment effect on curing the patient with MPA. | 04-28-2011 |
20110207662 | Composition for Long-Acting Peptide Analogs - The invention describes compositions of peptide analogs that are active in blood or cleavable in blood to release an active peptide. The peptide analogs have a general formula: A-(Cm) | 08-25-2011 |
20110212889 | USE OF LEPTIN FOR THE TREATMENT OF FATTY LIVER DISEASES AND CONDITIONS - The invention generally relates to the use of leptin in the treatment of a leptin-responsive disease or condition in a non-lipodystrophic subject. More particularly, the invention is directed to the use of leptin in the treatment of a fatty liver disease in a non-lipodystrophic subject with a relative leptin deficiency. The invention includes methods for the treatment of nonalcoholic steatohepatitis (NASH), alcoholic fatty liver disease (AFLD), and nonalcoholic fatty liver disease (NAFLD) in a non-lipodystrophic subject. The invention includes the treatment of conditions ranging from ectopic lipid accumulation (steatosis) to cirrhosis. | 09-01-2011 |
20120010132 | METHODS FOR TREATING PROGRESSIVE COGNITIVE DISORDERS RELATED TO NEUROFIBRILLARY TANGLES - The described invention provides methods for treating or preventing progression of a progressive cognitive disease, disorder or condition, and methods for improving resilience of cognitive function in a subject in need thereof. | 01-12-2012 |
20120035102 | AZINONE-SUBSTITUTED AZABICYCLOALKANE-INDOLE AND AZABICYCLOALKANE-PYRROLO-PYRIDINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF - Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are also described in the present invention. | 02-09-2012 |
20120058940 | AZINONE-SUBSTITUTED AZAPOLYCYCLE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF - Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are also described in the present invention. | 03-08-2012 |
20120149636 | Modified Leptin Polypeptides and Their Uses - Modified human leptin polypeptides and uses thereof are provided. | 06-14-2012 |
20120245084 | FORMULATIONS OF DILUTED AMINO ACID SEGMENTS AND METHODS FOR MAKING SAME - A formulation of a diluted amino acid segment is prepared by mixing an amino acid segment and a diluting agent to form a mixture. The mixture is serially diluted to produce a diluted formulation. The amino acid segment includes a peptide sequence that is the same as a portion of a longer peptide sequence found in a naturally occurring material. A homeopathic remedy can be prepared using the formulation. | 09-27-2012 |
20130023469 | LEPTIN FOR USE IN INCREASING LIVER REGENERATION - Activators of the AKT/mTOR pathway, in particular leptin, are useful in methods and compositions for increasing regeneration of liver, increasing liver mass or improving liver function, or a combination thereof. | 01-24-2013 |
20130023470 | EXENDIN AND EXENDIN AGONISTS FOR EATING DISORDERS - Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed. | 01-24-2013 |
20130065825 | Compositions and Methods for Delaying Senescence or Cell Death in Neurons - The described invention provides methods and compositions for enhancing the enzymatic activity of Sirtuin family members by using Leptin, Leptin analogs, Leptin derivatives, or Leptin agonists. The described invention further provides compositions and methods for delaying senescence or cell death in neurons using the compositions. | 03-14-2013 |
20130225488 | Antidiabetic Comppounds - The present invention provides novel peptidomimetics, of formula (I), which primarily act as glucose dependent insulin secretagogues. Furthermore, it was found that these peptidomimetics showed glucagon receptor antagonistic activity, along with the GLP-1 receptor agonistic activity. | 08-29-2013 |
20130231280 | Novel Peptide Involved in Energy Homeostasis - The expression of a mRNA encoding a putative 76 amino acid, secreted protein (“Enho1”) was found to negatively correlate with fasting triglyceride and cholesterol levels. A recombinant adenovirus was used to increase the expression of Enho1 mRNA in two mouse models of obesity, KK-A | 09-05-2013 |
20140088000 | Leptin Rescues Neurons from Alzheimer's Disease Related Pathways Triggered by Lipid Burden - The described invention relates to compositions and methods for rescuing neurons from Alzheimer's Disease related pathways triggered by lipid burden or metabolic insult. | 03-27-2014 |
20140094407 | DEVICES AND METHODS FOR TREATING AND/OR PREVENTING DISEASES - The invention relates to a therapeutic device for the delivery of therapeutic agents, e.g. a peptide such as leuprolide, via the vagina to a female mammal. In some embodiments, the invention also relates to methods for the treatment of obesity and eating disorders, diabetes, multiple sclerosis (MS), endometriosis, uterine fibroids, polycystic ovarian disease, various cancers such as breast cancer, acne, hirsutism, microbial or fungal or viral infections such as bacterial vaginosis or AIDS/HIV, and chronic diseases using a disclosed vaginal device. | 04-03-2014 |
20140121157 | METHODS FOR TREATING PROGRESSIVE COGNITIVE DISORDERS RELATED TO NEUROFIBRILLARY TANGLES - The described invention provides methods for treating or preventing progression of a progressive cognitive disease, disorder or condition, and methods for improving resilience of cognitive function in a subject in need thereof. | 05-01-2014 |
20140336111 | Therapeutic Use of Activators of Zinc Finger Protein GL13 - The present invention relates to the therapeutic use of activators of the zinc finger protein GLI3 in diseases that are associated with reduced Hedgehog signaling in hepatocytes, in particular Polycystic ovary syndrome, Steatosis hepatis, Steatohepatit is and/or Adipositas. The invention further relates to methods of treating an individual with said activator, a pharmaceutical composition comprising said activator and the use of said activator as food supplement. | 11-13-2014 |
20150038409 | Leptin Compositions and Methods for Treating Progressive Cognitive Function Disorders Resulting from Accumulation of Neurofibrillary Tangles and Amyloid Beta - The present disclosure provides compositions containing a leptin product and methods of clinical therapy and diagnostic methods for progressive cognitive disorders. According to one aspect, the described invention provides a method for treating a progressive cognitive disorder. According to another aspect, the described invention provides a method for improving resilience of cognitive function in a subject in need thereof. According to another aspect, the described invention provides a method for identifying an effective therapeutic agent for treating a progressive cognitive dysfunction disease or disorder that results from at least one of accumulation of Aβ, hyperphosphorylation of tau, or accumulation of neurofibrillary tangles. | 02-05-2015 |
20150355198 | Use of CD5 Antigen-Like as a Biomarker for Diabetic Nephropathy - Biomarkers for pre-Diabetes, Diabetes and/or a Diabetes related conditions, and methods of their use, including the biomarkers in Tables 1 and 2 such as peroxiredoxin-2, complement C1q subcomponent subunit B, sulfhydryl oxidase 1 and apolipoprotein A-IV. | 12-10-2015 |
20160058839 | LEPTIN FOR TREATING SYSTEMIC INFLAMMATORY RESPONSE SYNDROME - Provided are methods and compositions for reducing the severity of systemic inflammatory response syndrome (SIRS). The method comprises administering to an individual who has been diagnosed with SIRS, a composition comprising leptin. | 03-03-2016 |
20160102126 | Novel Peptides Involved in Energy Homeostasis - The expression of a mRNA encoding a putative 76 amino acid, secreted protein (“Enho1”) was found to negatively correlate with fasting triglyceride and cholesterol levels. A recombinant adenovirus was used to increase the expression of Enho1 mRNA in two mouse models of obesity, KK-A | 04-14-2016 |